AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1394812
Drug: Oral UFT
RxNorm normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral UFT given at 1296 mg/day for 2 years (group U)
Trial: 1394812
Drug: No prophylactic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No prophylactic treatment (group C)
Trial: 1394812
Drug: Oral UFT
RxNorm normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral UFT (group U)
Trial: 3900847
Drug: Tocopherol treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocopherol treatment (early parenteral tocopherol given from day one)
Trial: 19840063
Drug: Xanthigen-600/2.4 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xanthigen-600/2.4 mg (300 mg PSO + 300 mg brown seaweed extract containing 2.4 mg fucoxanthin)
Trial: 19840063
Drug: Fucoxanthin (>
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fucoxanthin (> 2.4 mg)
Trial: 19840063
Drug: Xanthigen-400/1.6 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xanthigen-400/1.6 mg (200 mg PSO + 200 mg brown seaweed extract containing 1.6 mg fucoxanthin)
Trial: 16982237
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no suppository treatment)
Trial: 1999775
Drug: Children with
RxNorm normalized name: Pediaclear Childrens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children with prevaccination antibody > 0.15 microgram/ml
Trial: 1999775
Drug: Children with
RxNorm normalized name: Pediaclear Childrens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children with prevaccination antibody ≤ 0.15 microgram/ml
Trial: 6141317
Drug: Beta-blocker group
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blocker group (Atenolol)
Trial: 6141317
Drug: Diuretic group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretic group (Hydrochlorothiazide)
Trial: 29431146
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment plus hyperbaric oxygen therapy (HBOT)
Trial: 26353751
Drug: Fixed Tc‐99m
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed Tc‐99m tetrofosmin tracer dose
Trial: 22864525
Drug: Intratympanic gadolinium
RxNorm normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratympanic gadolinium injection (gadolinium‐diethylene‐triamine pentaacetic acid diluted eightfold with saline)
Trial: 22864525
Drug: Intravenous gadolinium
RxNorm normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous gadolinium injection (double dose of gadoteridol (0.5 mmol/ml); 0.2 mmol/kg body weight)
Trial: 22864525
Drug: Intratympanic gadolinium
RxNorm normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratympanic gadolinium injection
Trial: 22864525
Drug: Intravenous gadolinium
RxNorm normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous gadolinium injection
Trial: 17475531
Drug: Continuous subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous insulin infusion (CSII) with bolus optimization and sulfonylurea at bedtime
Trial: 17475531
Drug: Continuous subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous insulin infusion (CSII) with basal rate optimization and sulfonylurea before meals
Trial: 16091670
Drug: Lifestyle intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lifestyle intervention (addition to pharmacological therapy)
Trial: 12041718
Drug: Polyethylene glycol
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyethylene glycol 3350 (10 g/m2/day)
Trial: 12041718
Drug: Lactulose (1.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactulose (1.3 g/kg/d divided twice daily up to 20 g)
Trial: 21383291
Drug: 3-day oral
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3-day oral aprepitant regimen (125 mg on day 1, 80 mg on day 2, 80 mg on day 3)
Trial: 21383291
Drug: Single-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose intravenous fosaprepitant (150 mg on day 1)
Trial: 10583029
Drug: Inhaled fluticasone
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fluticasone propionate (0.44 mg day-1, 0.88 mg day-1, 1.76 mg day-1)
Trial: 10583029
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone (5 mg day-1, 10 mg day-1, 20 mg day-1)
Trial: 1652264
Drug: 0.07 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.07 mg/kg pipecuronium
Trial: 1652264
Drug: 0.1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg/kg pipecuronium
Trial: 6848299
Drug: Atenolol 400
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atenolol 400 mg
Trial: 18704471
Drug: Fexofenadine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fexofenadine (60 mg BD)
Trial: 18704471
Drug: Cumulative amount
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cumulative amount of airborne pollen during the treatment period
Trial: 11982836
Drug: Oxycodone premedication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone premedication with halothane
Trial: 11982836
Drug: Halothane without
RxNorm normalized name: Halothane
DrugBank: Halothane (DB01159)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Halothane without oxycodone
Trial: 11982836
Drug: Sevoflurane without
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevoflurane without oxycodone
Trial: 11982836
Drug: Oxycodone premedication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone premedication with sevoflurane
Trial: 10593449
Drug: Olanzapine 12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine 12.5 mg/day for the first week, then 25 mg/day for the remaining weeks (8 weeks total)
Trial: 8618109
Drug: Cefetamet pivoxil
RxNorm normalized name: Cefetamet pivoxil
DrugBank: Cefetamet pivoxil (DB18915)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefetamet pivoxil 10 mg/kg bid for 5 days
Trial: 8618109
Drug: Cefetamet pivoxil
RxNorm normalized name: Cefetamet pivoxil
DrugBank: Cefetamet pivoxil (DB18915)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefetamet pivoxil 10 mg/kg bid for 10 days
Trial: 2169839
Drug: Lactulose (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactulose (15 ml bd)
Trial: 2169839
Drug: High-fibre diet
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fibre diet (30-40 g daily)
Trial: 7398187
Drug: Magnesium-aluminum hydroxide
RxNorm normalized name: Magnesium Aluminum Silicate
DrugBank: Magnesium Aluminum Silicate (DB11230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium-aluminum hydroxide gel 30 ml
Trial: 31672946
Drug: Customized Health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Customized Health Promotion Program (CHPP) for 10 weeks, weekly sessions, including coping strategies, lifestyle modification, emotional support, and exercise three times a week at home
Trial: 17852171
Drug: Immediate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate treatment (n = 177)
Trial: 15745977
Drug: Intrapleural streptokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrapleural streptokinase (250,000 IU twice daily for three days)
Trial: 12414852
Drug: Levothyroxine (L-T(4))
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levothyroxine (L-T(4))
Trial: 1742507
Drug: Oral bismuth
RxNorm normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral bismuth therapy
Trial: 6125728
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg acyclovir by mouth five times a day for 5 days
Trial: 29659406
Drug: Topical BTX‐A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical BTX‐A liposomal cream
Trial: 26704774
Drug: Morphine (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (0.1 mg/kg) plus lidocaine (1.5 mg/kg)
Trial: 26704774
Drug: Morphine (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (0.1 mg/kg) plus normal saline 0.9% (placebo)
Trial: 19757215
Drug: Sorafenib in
RxNorm normalized name: Product containing sorafenib in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib in patients with prior cytokine therapy
Trial: 19757215
Drug: Placebo in
RxNorm normalized name: placebo INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in patients with prior cytokine therapy
Trial: 18755514
Drug: Fluoxetine (20-60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (20-60 mg daily, flexible-dose)
Trial: 16780494
Drug: 1072-nm light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1072-nm light treatment
Trial: 4067130
Drug: 0.5 ppm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 ppm of sulfur dioxide (SO2) via oral inhalation
Trial: 4067130
Drug: 0.5 ppm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 ppm of sulfur dioxide (SO2) via oronasal inhalation (face mask)
Trial: 30240978
Drug: Computer-based cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer-based cognitive-behavioral therapy (CBT4CBT) plus treatment as usual (TAU)
Trial: 30240978
Drug: Outpatient treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient treatment as usual (TAU)
Trial: 24439741
Drug: Interrupted transdermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interrupted transdermal suture
Trial: 22960288
Drug: Exenatide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide (10 μg, single subcutaneous injection)
Trial: 18799552
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (23-valent pneumococcal polysaccharide vaccine)
Trial: 15707442
Drug: Cognitive coping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive coping intervention administered over three consecutive days in 20-30 minute sessions.
Trial: 12125806
Drug: Estrogen replacement
RxNorm normalized name: Norethindrone Acetate 1mg, Ethinyl Estradiol 5mcg Oral tablet [Estrogen Replacement/Osteoporosis]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen replacement therapy (ERT) and hormone replacement therapy (HRT)
Trial: 2140370
Drug: TCMP‐80 (0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCMP‐80 (0.01 mg/kg to 10 mg/kg)
Trial: 30945492
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (puncturing specific acupoints below the spinous processes from T3 to T12, once every other day for 8 weeks)
Trial: 30945492
Drug: Medication group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication group (omeprazole capsules 20 mg, twice a day for 8 weeks)
Trial: 26028518
Drug: Androgen deprivation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen deprivation therapy (ADT; goserelin 10·8 mg every 3 months for 3 years) plus four cycles of docetaxel (70 mg/m² on day 2) and estramustine (10 mg/kg per day on days 1-5, every 3 weeks)
Trial: 17265078
Drug: Tiagabine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiagabine (15 mg/day)
Trial: 14692927
Drug: Post punch‐grafting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post punch‐grafting topical application of fluocinolone acetonide 0.1% (group II)
Trial: 11009194
Drug: Cued physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cued physical therapy
Trial: 11009194
Drug: Non-cued physical
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-cued physical therapy
Trial: 9180192
Drug: 40 microg
RxNorm normalized name: Travoprost 40 microgram/mL eye drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 microg and 20 microg doses at 0 and 6 months
Trial: 9180192
Drug: Three 10-microg
RxNorm normalized name: THREE-LOBE SAGE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three 10-microg doses at 0, 1, and 6 months
Trial: 8238144
Drug: Aspirin with
RxNorm normalized name: Bayer Aspirin with Calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin with fourfold thromboxane B2 reduction
Trial: 27798902
Drug: Trastuzumab (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab (8 mg/kg) and Paclitaxel (90 mg/m2) every three weeks
Trial: 20225477
Drug: Gel-to-foam dentifrice
RxNorm normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gel-to-foam dentifrice (Aquafresh Iso-active)
Trial: 17381486
Drug: EMLA cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA cream (2.5 g)
Trial: 15367249
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg of bupropion SR daily and PTC (n=382)
Trial: 15367249
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg of bupropion SR daily and PTC (n=383)
Trial: 15367249
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg of bupropion SR daily and TM (n=381)
Trial: 15367249
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg of bupropion SR daily and TM (n=378)
Trial: 11318882
Drug: Tizanidine hydrochloride
RxNorm normalized name: Tizanidine Hydrochloride
DrugBank: Tizanidine (DB00697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tizanidine hydrochloride tablets (median daily dose of 14 mg, mean 13.5 mg, SD 4.3, range 4 to 20 mg, divided over three doses per day)
Trial: 11318882
Drug: Tizanidine hydrochloride
RxNorm normalized name: Tizanidine Hydrochloride
DrugBank: Tizanidine (DB00697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tizanidine hydrochloride tablets
Trial: 9840539
Drug: High fiber
RxNorm normalized name: High Fiber Gummies Soft Chew
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High fiber supplement
Trial: 31133494
Drug: Three consecutive
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three consecutive monthly treatments with selamectin (5.25–6.60 mg/kg) and sarolaner (0.88–1.10 mg/kg) on Days 0, 30, and 60
Trial: 31133494
Drug: Single treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single treatment with fluralaner (34.71–43.08 mg/kg) on Day 0 and placebo on Days 30 and 60
Trial: 28403598
Drug: Antibiotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic therapy with Prulifloxacine, 400 mg/day for 5 days
Trial: 28403598
Drug: Association of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Association of D-mannose and NAC therapy, two vials/day for 7 days
Trial: 24267043
Drug: Cayenne pepper
RxNorm normalized name: Cayenne pepper
DrugBank: Red pepper (DB14759)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cayenne pepper (500 mg, 1.25 mg capsaicin)
Trial: 24267043
Drug: Evodiamine (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evodiamine (500 mg)
Trial: 22384541
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Wenshen Yangxue Granule (WSYXG) and Clomifene Citrate (CC)
Trial: 16427437
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate (120 to 150 mg a day continuous infusion)
Trial: 16427437
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (prophylactic hypervolemic and hemodilution therapy plus nimodipine)
Trial: 2961362
Drug: L-714,465 (0-4%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-714,465 (0-4%)
Trial: 28156253
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment in patients with severe carotid stenosis (≥ 70%)
Trial: 28156253
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment in patients with less than 70% stenosis (< 70%)
Trial: 22906959
Drug: Quadrivalent vaccine
RxNorm normalized name: PAPILLOMAVIRUS HUMAN QUADRIVALENT VACCINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent vaccine (Gardasil; Merck)
Trial: 22906959
Drug: Bivalent vaccine
RxNorm normalized name: PAPILLOMAVIRUS BIVALENT VACCINE INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalent vaccine (Cervarix; GlaxoSmithKline)
Trial: 18540910
Drug: Naltrexone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (100 mg/d) + Cognitive‐Behavioral Therapy (CBT) + medication clinic
Trial: 18540910
Drug: Naltrexone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (100 mg/d) + BRENDA + medication clinic
Trial: 18540910
Drug: Naltrexone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (100 mg/d) + medication clinic with limited therapeutic content
Trial: 18540910
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + Cognitive‐Behavioral Therapy (CBT) + medication clinic
Trial: 18540910
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + BRENDA + medication clinic
Trial: 18540910
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + medication clinic with limited therapeutic content
Trial: 12925457
Drug: HEPACOAT stent
RxNorm normalized name: castor fiber scent gland secretion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HEPACOAT stent with aspirin alone
Trial: 6337611
Drug: mianserin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mianserin (30 to 90 mg)
Trial: 6337611
Drug: maprotiline (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: maprotiline (75 to 225 mg)
Trial: 6337611
Drug: placebo (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (1 to 3 capsules)
Trial: 25649338
Drug: Percutaneous electric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous electric neurostimulation (PENS) of dermatome T7 (12 sessions of 30 minutes weekly) associated with a 1,200 Kcal/day diet
Trial: 23179965
Drug: THC (0.015
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THC (0.015 to 0.05 mg/kg)
Trial: 21834670
Drug: 5% topical
RxNorm normalized name: BP 5% Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% topical povidone-iodine
Trial: 19366970
Drug: Taspoglutide 5
RxNorm normalized name: Taspoglutide
DrugBank: Taspoglutide (DB14027)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taspoglutide 5 mg once weekly
Trial: 22937895
Drug: Taspoglutide 10
RxNorm normalized name: Taspoglutide
DrugBank: Taspoglutide (DB14027)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taspoglutide 10 mg once weekly
Trial: 22937895
Drug: Taspoglutide 20
RxNorm normalized name: Taspoglutide
DrugBank: Taspoglutide (DB14027)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taspoglutide 20 mg once weekly
Trial: 19366970
Drug: Taspoglutide 10
RxNorm normalized name: Taspoglutide
DrugBank: Taspoglutide (DB14027)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taspoglutide 10 mg once every 2 weeks
Trial: 19366970
Drug: Taspoglutide 20
RxNorm normalized name: Taspoglutide
DrugBank: Taspoglutide (DB14027)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taspoglutide 20 mg once every 2 weeks
Trial: 8963158
Drug: Levocabastine eye
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levocabastine eye drops (0.5 mg/ml, single dose)
Trial: 8963158
Drug: Levocabastine eye
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levocabastine eye drops (0.5 mg/ml, one drop in each eye twice daily for two weeks)
Trial: 6345281
Drug: ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ursodeoxycholic acid 12 mg/kg
Trial: 30970218
Drug: ω‐3 supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ω‐3 supplementation (3 g eicosapentaenoic acid, 2 g docosahexaenoic acid)
Trial: 26589401
Drug: Supervised rehabilitation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised rehabilitation therapy (weekly sessions with facial exercises and massages, daily facial exercises at home)
Trial: 26589401
Drug: Daily homework
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily homework manual for ordinary postoperative facial mimic exercises (autonomously at home)
Trial: 19091127
Drug: 12 mg/day
RxNorm normalized name: EMSAM 12 MG/Day 24HR Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg/day of astaxanthin